Long-term Balancing Act: Incentives and FOBs Pathway
This article was originally published in RPM Report
As Congress finishes its work on a pathway for follow-on biologics, a number of key decisions affecting incentives for copies and innovative products remain. No matter how the new legislation turns out, a number of issues will remain to be worked out in practice and will dominate investment and drug development policy for decades to come.
You may also be interested in...
Congress has moved into the final horse-trading phase of policy development regarding incentives for innovators and biosimilar product developers. The main question on Capitol Hill is what compromise can generate enough support to survive the political process. Jeffrey MOe, a Duke business school professor with experience developing incentives for drug development policy, suggest Congress should reflect before forging its political decision.